初诊慢性髓性白血病患者一线达沙替尼与伊马替尼治疗的健康相关生活质量比较
多中心倾向匹配病例对照研究比较初诊CML患者一线达沙替尼(100例)与伊马替尼(223例)的健康相关生活质量。达沙替尼组在日常生活影响、社交生活满意度和症状负担方面报告更优的疾病特异性HRQOL结局;在60岁及以上患者中,达沙替尼的获益在多个通用和疾病特异性HRQOL领域可忽略不计。
要点
- 达沙替尼组日常生活影响评分优于伊马替尼组(Δ=8.72,95%CI 3.17-14.27,p=0.002)。
- 达沙替尼组社交生活满意度(Δ=13.45,95%CI 5.82-21.08,p=0.001)和症状负担(Δ=7.69,95%CI 3.42-11.96,p=0.001)更优。
- 60岁及以上患者中,达沙替尼在多个HRQOL领域的优势可忽略不计。
核心结论
- 一线达沙替尼治疗的初诊CML患者报告比伊马替尼治疗者更好的疾病特异性HRQOL结局,尤其在日常生活影响、社交生活满意度和症状负担方面。
- 在60岁及以上患者中,达沙替尼相对于伊马替尼的HRQOL优势在多个领域可忽略不计。
研究设计与样本
- 多中心倾向匹配病例对照研究,比较初诊CML患者一线达沙替尼(病例)与伊马替尼(对照)的HRQOL。
- 共纳入323例CML患者,其中伊马替尼组223例,达沙替尼组100例。
- 采用EORTC QLQ-C30和EORTC QLQ-CML24问卷评估患者报告HRQOL,主要比较指标为EORTC QLQ-CML24的日常生活影响量表。
主要发现
- 达沙替尼组日常生活影响评分优于伊马替尼组(Δ=8.72,95%CI 3.17-14.27,p=0.002)。
- 达沙替尼组社交生活满意度优于伊马替尼组(Δ=13.45,95%CI 5.82-21.08,p=0.001)。
- 达沙替尼组症状负担优于伊马替尼组(Δ=7.69,95%CI 3.42-11.96,p=0.001)。
- 在60岁及以上患者中,达沙替尼在多个癌症通用和疾病特异性HRQOL领域的差异可忽略不计。
临床怎么用
- 研究提供的比较性HRQOL数据可扩展对两种TKI安全性和疗效的认识,可能有助于促进一线治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17-14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82-21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42-11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.
引用
- Efficace F, Stagno F, Iurlo A, et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia. 2019. PMID: 31477798. doi:10.1038/s41375-019-0563-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。